Fastigium biotechnology consists of the co-transfection of mRNA with helper RNAs.
These single-stranded RNA molecules have several hundred nucleotides and are mixed with the mRNA at a molar ratio of less than 1:100.
The translation efficiency of mRNA is enhanced in transfected cells.
This allows the administration to patients of a lower dose of mRNA to achieve the same level of protein expression.
This will decrease the cost of the mRNA product and improve its tolerance by patients.